- |||||||||| EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial primary completion date, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Apr 19, 2015 P1, N=30, Recruiting, Trial primary completion date: Dec 2013 --> Jun 2015 Trial primary completion date: Feb 2015 --> Jul 2015
- |||||||||| Biomarker, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Apr 14, 2015
P2, N=610, Not yet recruiting, Trial primary completion date: Oct 2017 --> Jun 2016 Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2019 --> Nov 2020
- |||||||||| Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Genistein in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 14, 2015 P1/2, N=24, Recruiting, Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2019 --> Nov 2020 Trial primary completion date: Apr 2015 --> May 2016
- |||||||||| Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Apr 14, 2015 P1, N=20, Recruiting, Trial primary completion date: Dec 2015 --> Jul 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- |||||||||| oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Surgery, Post-surgery: A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 14, 2015 P2, N=21, Active, not recruiting, Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- |||||||||| ipatasertib (RG7440) / Roche
Enrollment closed, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 3, 2015 P1, N=122, Active, not recruiting, Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Jun 2016 Recruiting --> Active, not recruiting
- |||||||||| Fotivda (tivozanib) / Kyowa Kirin, LG Chem
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy (clinicaltrials.gov) - Apr 3, 2015 P2, N=265, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Sep 2013
- |||||||||| Enrollment closed, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Mar 25, 2015
P2/3, N=714, Active, not recruiting, Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- |||||||||| Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Enrollment change, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 23, 2015 P1, N=43, Active, not recruiting, Active, not recruiting --> Completed N=33 --> 43
- |||||||||| Avastin (bevacizumab) / Roche
Biomarker, Enrollment closed, Combination therapy, Metastases: AC-ANGIOPREDICT: ANGIOPREDICT. ICORG 12-16, V3 (clinicaltrials.gov) - Mar 17, 2015 P2, N=224, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
|